Sirolimus Administration Does Not Affect Growth Parameters in Children with Vascular Anomalies Treated for 2 Years or More
Sirolimus has been identified as an effective medication in patients of all ages diagnosed with various vascular anomalies. Although the medication’s safety and efficacy have been well published in the last decade, the effect of sirolimus on growth parameters (height and weight) has not been thoroughly analyzed. We performed a retrospective chart review over a large cohort of patients with vascular anomalies treated at our center. We found that sirolimus does not adversely affect growth in patients on consistent and long-term use of sirolimus when controlled for age and gender.
Authors
- Ionela Iacobas (ORCID: https://orcid.org/0000-0002-9259-8761)
- Marisa Rao
- Jesline Simon
Institutions
- University of North Texas (US)
- University of North Texas Health Science Center (US)
- Texas College (US)
- Texas Children's Hospital (US)
- University of Houston (US)
Publication Details
- Journal
- Journal of Vascular Anomalies
- Published
- 2026-04-02
- DOI
- https://doi.org/10.1097/jova.0000000000000139
- Primary Topic
- Vascular Malformations and Hemangiomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00